help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Szulc, P.
Right arrow Articles by Delmas, P. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Szulc, P.
Right arrow Articles by Delmas, P. D.
The Journal of Clinical Endocrinology & Metabolism Vol. 86, No. 7 3162-3165
Copyright © 2001 by The Endocrine Society

Original Articles

Osteoprotegerin Serum Levels in Men: Correlation with Age, Estrogen, and Testosterone Status1

P. Szulc, L. C. Hofbauer, A. E. Heufelder, S. Roth and P. D. Delmas

INSERM, U-403, Hopital Edouard Herriot (P.S., P.D.D.), 69437 Lyon, France; Division of Gastroenterology, Endocrinology, and Metabolism, Philipps University (L.C.H., A.E.H.), 35033 Marburg, Germany; and Immundiagnostik (S.R.), 64625 Bensheim, Germany

Address all correspondence and requests for reprints to: Pierre D. Delmas, M.D., Ph.D., INSERM, U-403, Hopital Edouard Herriot, place d’Arsonval 3, 69437 Lyon, France. E-mail: delmas{at}lyon151.inserm.fr

Abstract

Previous studies have suggested an important role for androgens and estrogens in bone metabolism in men. However, their local mode of action has not been clearly established. Osteoprotegerin (OPG) is a secreted decoy receptor that inhibits osteoclast formation and activity by neutralizing its cognate ligand. To assess the role of OPG on bone metabolism in men, we conducted a study aimed at evaluating OPG serum levels and their correlation with age, bone mineral density, biochemical markers of bone turnover, and testosterone and estradiol levels in 252 men, aged 19–85 yr. Serum concentrations of OPG increased significantly with age (r = 0.41; P = 0.0001), and were positively correlated with free testosterone index and free estradiol index (r = 0.20; P < 0.002 and r = 0.15; P < 0.03, respectively) after adjustment for age and body weight. Beyond the age of 40 yr, OPG serum concentrations were negatively correlated with urinary excretion of total deoxypyridinoline (r = -0.20; P < 0.01) and PTH serum levels (r = -0.23; P < 0.01). In contrast, there was no correlation with biochemical markers of bone formation, 25-hydroxyvitamin D3 levels, or bone mineral density at any site. Our data reveal that age as well as androgen and estrogen status are significant positive determinants, whereas PTH is a negative determinant, of OPG serum levels in men. These data suggest that OPG may be an important paracrine mediator of bone metabolism in elderly men and highlight the role of estrogens in the homeostasis of the male skeleton.




This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
E. J. Samelson, K. E. Broe, S. Demissie, T. J. Beck, D. Karasik, S. Kathiresan, and D. P. Kiel
Increased Plasma Osteoprotegerin Concentrations Are Associated with Indices of Bone Strength of the Hip
J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1789 - 1795.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
A. E. Kearns, S. Khosla, and P. J. Kostenuik
Receptor Activator of Nuclear Factor {kappa}B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease
Endocr. Rev., April 1, 2008; 29(2): 155 - 192.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
M.-H. Gannage-Yared, C. Yaghi, B. Habre, S. Khalife, R. Noun, M. Germanos-Haddad, and V. Trak-Smayra
Osteoprotegerin in relation to body weight, lipid parameters insulin sensitivity, adipocytokines, and C-reactive protein in obese and non-obese young individuals: results from both cross-sectional and interventional study
Eur. J. Endocrinol., March 1, 2008; 158(3): 353 - 359.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
D. V. Anand, E. Lim, D. Darko, P. Bassett, D. Hopkins, D. Lipkin, R. Corder, and A. Lahiri
Determinants of Progression of Coronary Artery Calcification in Type 2 Diabetes: Role of Glycemic Control and Inflammatory/Vascular Calcification Markers
J. Am. Coll. Cardiol., December 4, 2007; 50(23): 2218 - 2225.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
F. Joseph, B. Y. Chan, B. H. Durham, A. M. Ahmad, S. Vinjamuri, J. A. Gallagher, J. P. Vora, and W. D. Fraser
The Circadian Rhythm of Osteoprotegerin and Its Association with Parathyroid Hormone Secretion
J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3230 - 3238.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
G. Saviola, L. Abdi. Ali, S. Shams. Eddin, A. Coppini, F. Cavalieri, L. Campostrini, S. Sacco, M. Bucci, G. Cirino, and M. Rossini
Compared clinical efficacy and bone metabolic effects of low-dose deflazacort and methyl prednisolone in male inflammatory arthropathies: a 12-month open randomized pilot study
Rheumatology, June 1, 2007; 46(6): 994 - 998.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
A. Stern, G. A Laughlin, J. Bergstrom, and E. Barrett-Connor
The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor {kappa}B legend with bone mineral density in older adults: the Rancho Bernardo Study
Eur. J. Endocrinol., May 1, 2007; 156(5): 555 - 562.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Dovio, B. Allasino, E. Palmas, M. Ventura, A. Pia, L. Saba, E. Aroasio, M. Terzolo, and A. Angeli
Increased Osteoprotegerin Levels in Cushing's Syndrome Are Associated with an Adverse Cardiovascular Risk Profile
J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1803 - 1808.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
J. Y. Shin, Y. G. Shin, and C. H. Chung
Elevated Serum Osteoprotegerin Levels Are Associated With Vascular Endothelial Dysfunction in Type 2 Diabetes
Diabetes Care, July 1, 2006; 29(7): 1664 - 1666.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
D. V. Anand, A. Lahiri, E. Lim, D. Hopkins, and R. Corder
The Relationship Between Plasma Osteoprotegerin Levels and Coronary Artery Calcification in Uncomplicated Type 2 Diabetic Subjects
J. Am. Coll. Cardiol., May 2, 2006; 47(9): 1850 - 1857.
[Abstract] [Full Text] [PDF]

Home page
 Alcohol AlcoholHome page
E. GARCIA-VALDECASAS-CAMPELO, E. GONZALEZ-REIMERS, F. SANTOLARIA-FERNANDEZ, M. J. DE LA VEGA-PRIETO, A. MILENA-ABRIL, M. J. SANCHEZ-PEREZ, A. MARTINEZ-RIERA, and M. D. L. A. GOMEZ-RODRIGUEZ
SERUM OSTEOPROTEGERIN AND RANKL LEVELS IN CHRONIC ALCOHOLIC LIVER DISEASE
Alcohol Alcohol., May 1, 2006; 41(3): 261 - 266.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Rogers and R. Eastell
Circulating Osteoprotegerin and Receptor Activator for Nuclear Factor {kappa}B Ligand: Clinical Utility in Metabolic Bone Disease Assessment
J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6323 - 6331.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
A. Avignon, A. Sultan, C. Piot, S. Elaerts, J. P. Cristol, and A. M. Dupuy
Osteoprotegerin Is Associated With Silent Coronary Artery Disease in High-Risk but Asymptomatic Type 2 Diabetic Patients
Diabetes Care, September 1, 2005; 28(9): 2176 - 2180.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
K. M. Wiren, X.-W. Zhang, A. R. Toombs, V. Kasparcova, M. A. Gentile, S.-I. Harada, and K. J. Jepsen
Targeted Overexpression of Androgen Receptor in Osteoblasts: Unexpected Complex Bone Phenotype in Growing Animals
Endocrinology, July 1, 2004; 145(7): 3507 - 3522.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
K. E. Naylor, A. Rogers, R. B. Fraser, V. Hall, R. Eastell, and A. Blumsohn
Serum Osteoprotegerin as a Determinant of Bone Metabolism in a Longitudinal Study of Human Pregnancy and Lactation
J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5361 - 5365.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Schoppet, A. M. Sattler, J. R. Schaefer, M. Herzum, B. Maisch, and L. C. Hofbauer
Increased Osteoprotegerin Serum Levels in Men with Coronary Artery Disease
J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1024 - 1028.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Rogers, G. Saleh, R. A. Hannon, D. Greenfield, and R. Eastell
Circulating Estradiol and Osteoprotegerin as Determinants of Bone Turnover and Bone Density in Postmenopausal Women
J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4470 - 4475.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. Rubin, C. L. Ackert-Bicknell, L. Zhu, X. Fan, T. C. Murphy, M. S. Nanes, R. Marcus, L. Holloway, W. G. Beamer, and C. J. Rosen
IGF-I Regulates Osteoprotegerin (OPG) and Receptor Activator of Nuclear Factor-{kappa}B Ligand in Vitro and OPG in Vivo
J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4273 - 4279.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
G. Coen, P. Ballanti, A. Balducci, S. Calabria, M. S. Fischer, L. Jankovic, M. Manni, M. Morosetti, E. Moscaritolo, D. Sardella, et al.
Serum osteoprotegerin and renal osteodystrophy
Nephrol. Dial. Transplant., February 1, 2002; 17(2): 233 - 238.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2001 by The Endocrine Society